Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease

CNS Drugs

Volumn 26, Issue 12, 2012, Pages 1017-1032

  Duty, Susan ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 ADAMANTYLMETHYLAMMONIO) 5 TRIMETHYLAMMONIOPENTANE DIBROMIDE; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMANTADINE; AMN 082; AMPA RECEPTOR ANTAGONIST; BESONPRODIL; CABERGOLINE; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DIPRAGLURANT; DIZOCILPINE; FENOBAM; GLUTAMATE RECEPTOR; IFENPRODIL; LEVODOPA; LY 503430; MEMANTINE; METABOTROPIC RECEPTOR AGONIST; N [2 [4 (4 CYANOPHENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OCTAHYDRO 4 HYDROXY 4 [(3 METHYLPHENYL)ETHYNYL] 1H INDOLE 1 CARBOXYLIC ACID METHYL ESTER; PERAMPANEL; PLACEBO; TALAMPANEL; TEZAMPANEL; TOPIRAMATE; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BRAIN REGION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COGNITION; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG TARGETING; DYSKINESIA; HUMAN; LEVODOPA INDUCED DYSKINESIA; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84873417885     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0016-z     Document Type: Article

References (186)

1. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. European community concerted action on the epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62(1):10-5.
2. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464-74.
3. Lang AE, Lozano AM. Parkinson's disease: first of two parts. N Engl J Med. 1998;339(15):1044-53.
4. Blandini F, Nappi G, Tassorelli C, et al. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol. 2000;62(1):63-88.
5. Isaacson SH, Hauser RA. Improving symptom control in early Parkinson's disease. Ther Adv Neurol Disord. 2009;2(6):29-41.
6. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1997;1(8007):345-9.
7. Hametner E, Seppi K, Poewe W. The clinical spectrum of levodopa-induced motor complications. J Neurol. 2010;257(Suppl. 2):S268-75.
8. Blandini F, Porter RH, Greenamayre JT. Glutamate and Parkinson's disease. Mol Neurobiol. 1996;12(1):73-94.
9. Hirsch EC, Périer C, Orieux G, et al. Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci. 2000;23(10 Suppl):S78-85.
10. Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord. 2008;23(Suppl. 3):S548-59.
11. Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011;164(4):1357-91.
12. Kashani A, Batancur C, Giros B, et al. Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson's disease. Neurobiol Aging. 2007;28(4):568-78.
13. Jiménez-Jiménez FJ, Molina JA, Vargas C, et al. Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease. J Neurol Sci. 1996;141(1-2):39-44.
14. Kuiper MA, Teerlink T, Visser JJ, Bergmans PLM, et al. l-Glutamate, l-arginine and l-cirtulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's patients. J Neural Transm. 2000;107(2):183-9.
15. Ondarza R, Velasco F, Velasco M, et al. Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson's disease. Stereotact Funct Neurosurg. 1994;62(1-4):90-7.
16. Gerlach M, Gsell W, Kornhuber J, et al. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia thalamo-cortical circuits in Parkinson syndrome. Brain Res. 1996;741(1-2):142-52.
17. Rinne JO, Halonen T, Riekkinen PJ, et al. Free amino acids in the brain of patients with Parkinson's disease. Neurosci Lett. 1988;94(1-2):182-6.
18. Cenci MA, Lundblad M. Post- versus presynaptic plasticity in l-dopa-induced dyskinesia. J Neurochem. 2006;99(2):381-92.
19. Jenner P. Molecular mechanisms of l-dopa-induced dyskinesia. Nat Rev Neurosci. 2008;9(9):665-77.
20. Calabresi P, Di Fillippo M, Ghiglieri V, et al. Levodopa-induced dyskinesia in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 2010;9(11):1106-17.
21. Iravani MM, McCreary AC, Jenner P. Striatal plasticity in Parkinson's disease and l-dopa-induced dyskinesia. Parkinsonism Relat Disord. 2012;18(Suppl. 1):S123-5.
22. Sgambato-Faure V, Cenci MA. Glutamatergic mechanisms in the dyskinesia induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog Neurobiol. 2012;96(1):69-86.
23. Blandini F, Armentero MT. New pharmacological avenues for the treatment of l-dopa-induced dyskinesia in Parkinson's disease: targeting glutamate and adenosine receptors. Expert Opin Investig Drugs. 2012;21(2):153-68.
24. Dupre KB, Ostock CY, Eskow Juanarajs KL, et al. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol. 2011;229(2):288-99.
25. Samadi P, Grégoire L, Morissette M, et al. mGluR5 metabotropic glutamate receptors and dyskinesia in MPTP monkeys. Neurobiol Aging. 2008;29(7):1040-51.
26. Outtara B, Grégoire L, Mirissette M, et al. Metabotropic glutamate receptor 5 in levodopa-induced motor complications. Neurobiol Aging. 2011;32(7):1286-95.
27. Samadi P, Grégoire L, Morissette M, Calon F. Hadj Tahar A, Bélanger N, Dridi M, Bédard PJ, Di Paolo T. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of l-dopa-induced dyskinesias. Neuropharmacology. 2008;54(2):258-68.
28. Samadi P, Rajput A, Calon F, Grégoire L, Hornykiewicz O, Rajput AH, Di Paolo T. Metabotropic glutamate receptor II in the brains of Parkinsonian patients. J Neuropathol Exp Neurol. 2009;68(4):374-82.
29. Calon F, Rajput AH, Hornykiewicz O, et al. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis. 2003;14(3):404-16.
30. Hallett PJ, Dunah AW, Ravenscroft P, et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology. 2005;48(4):503-16.
31. Gardoni F, Sgobio C, Pendolino V, et al. Targeting NR2A-containing NMDA receptors reduces l-dopa-induced dyskinesia. Neurobiol Aging. 2012;33(9):2138-44.
32. Calon F, Morissette M, Ghribi O, et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(1):127-38.
33. Outtara B, Hoyer D, Grégoire L, et al. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience. 2010;167(4):1160-7.
34. Hurley MJ, Jackson MJ, Smith LA, et al. Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. Eur J Neurosci. 2005;21(12):3240-50.
35. Ahmed I, Bose SK, Pavese N, et al. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain. 2011;134(4):979-86.
36. Santini E, Valjent E, Usiello A, et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-dopa-induced dyskinesia. J Neurosci. 2007;27(26):6995-7005.
37. Ba M, Kong M, Yu G, et al. GluR1 phosphorylation and persistent expression of levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurochem Res. 2011;36(6):1135-44.
38. Santini E, Sgamboto-Faure V, Li Q, et al. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in l-dopa-induced dyskinesia. PLoS One. 2010;5(8):e12322.
39. Wang JQ, Arora A, Yang L, et al. Phosphorylation of AMPA receptors: mechanisms and synaptic plasticity. Mol Neurobiol. 2005;32(3):237-49.
40. Ba M, Kong M, Yang H, et al. Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa treated rats. Neurochem Res. 2006;31(11):1337-47.
41. Silverdale MA, Kobylecki C, Hallett PJ, et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse. 2010;64(2):177-80.
42. Oh JD, Russell DS, Vaughan CL, et al. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and l-dopa administration. Brain Res. 1998;813(1):150-9.
43. Gardoni F, Picconi B, Ghiglieri V, et al. A critical interaction between NR2B and MAGUK in l-dopa-induced dyskinesia. J Neurosci. 2006;26(11):2914-22.
44. Muñoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-dopa-induced dyskinesia. Brain. 2008;131(12):3380-4.
45. Picconi B, Centonze D, Håkansson K, et al. Loss of bidirectional striatal synaptic plasticity in l-dopa-induced dyskinesia. Nat Neurosci. 2003;6(5):501-6.
46. Massey PV, Johnson BE, Moult PR, et al. Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci. 2004;24(36):7821-8.
47. Olanow CW. The pathogenesis of cell death in Parkinson's disease. Mov Disord. 2007;22(Suppl. 17):S335-42.
48. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord. 2011;26(6):1049-55.
49. Blandini F. An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct Neurol. 2010;25(2):65-71.
50. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch Eur J Physiol. 2010;460(2):525-42.
51. Bevan MD, Bolam JP, Crossman AR. Convergent synaptic input from the neostriatum and the subthalamus onto identified nigrothalamic neurons in the rat. Eur J Neurosci. 1994;6(3):320-34.
52. Kornhuber J, Kim JS, Kornhuber ME, et al. The cortico-nigral projection: reduced glutamate content in the substantia nigra following frontal cortex ablation in the rat. Brain Res. 1984;322(1):124-6.
53. Helton TD, Otsuka T, Lee M-C, et al. Pruning and loss of excitatory synapses by the parkin ubiquitin ligase. Proc Natl Acad Sci USA. 2008;105(49):19492-7.
54. Lücking CB, Dürr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med. 2000;342(21):1560-7.
55. Abou-Sleiman PM, Healy DG, Wood NW. Causes of Parkinson's disease: genetics of DJ-1. Cell Tissue Res. 2004;318(1):185-8.
56. Aleyasin H, Rousseaux MWC, Phillips M, et al. The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage. Proc Natl Acad Sci USA. 2007;104(47):18748-53.
57. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology. 1992;42(4):733-8.
58. Sawada H, Shimohama S, Tamura Y, et al. Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultures rat mesencephalon. J Neurosci Res. 1996;43(1):55-62.
59. Hatcher JM, Pennell KD, Miller GW. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci. 2008;29(6):322-9.
60. Wu YN, Johnson SW. Rotenone reduces Mg2+-dependent block of NMDA currents in substantia nigra dopamine neurons. Neurotoxicology. 2009;30(2):320-5.
61. Shimizu K, Matsubara K, Ohtaki K, et al. Paraquat leads to dopaminergic neuronal vulnerability in organotypic midbrain cultures. Neurosci Res. 2003;46(4):523-32.
62. Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 1995;15(4):961-73.
63. Tatton WG, Chalmers-Redman R, Brown D, et al. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol. 2003;53(Suppl. 3):S61-70.
64. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol. 1992;32(6):804-12.
65. Chatha BT, Bernard V, Streit P, et al. Synaptic localization of ionotropic glutamate receptors in the rat substantia nigra. Neuroscience. 2000;101(4):1037-51.
66. Bernard V, Somogyi P, Bolam JP. Cellular, subcellular, and subsynaptic distribution of AMPA-type glutamate receptor subunits in the neostriatum of the rat. J Neurosci. 1997;17(2):819-33.
67. Klockgether T, Turski L, Honoré T, et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol. 1991;39(5):717-23.
68. Löschmann PA, Lange KW, Kunow M, et al. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with l-dopa in models of Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1991;3(3):203-13.
69. Luquin MR, Obeso JA, Laguna J, et al. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur J Pharmacol. 1993;235(2-3):297-300.
70. Konitsiotis S, Blanchet PJ, Verhagen L, et al. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 2000;54(8):1589-95.
71. Silverdale MA, Nicholson SL, Crossman AR, et al. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord. 2005;20(4):403-9.
72. Marin C, Jimenez A, Bonastre M, et al. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse. 2001;42(1):40-7.
73. Eggert K, Squillacote D, Barone P, et al. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov Disord. 2010;25(7):896-905.
74. Lees A, Fahn S, Eggert KM, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord. 2012;27(2):284-8.
75. Kobylecki C, Cenci MA, Crossman AR, et al. Calcium-permeable AMPA receptors are involved in the induction and expression of l-dopa-induced dyskinesia in Parkinson's disease. J Neurochem. 2010;114(2):499-511.
76. Turski L, Bressler K, Rettig KJ, et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-d-aspartate antagonists. Nature. 1991;349(6308):414-8.
77. Murray TK, Whalley K, Robinson CS, et al. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther. 2003;306(2):752-62.
78. O'Neill MJ, Murray TK, Whalley K, et al. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease. Eur J Pharmacol. 2004;486(2):163-74.
79. Muir KW, Grosset DG, Gamzu E, et al. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin Pharmacol. 1994;38(1):33-8.
80. Low SJ, Roland CL. Review of NMDA antagonist-induced neurotoxicity and implications for clinical development. Int J Clin Pharmacol Ther. 2004;42(1):1-14.
81. Carlsson M, Svensson A. The non-competitive NMDA antagonists MK-801 and PCP, as well as the competitive NMDA antagonist SDZEAA494 (D-CPPene), interact synergistically with clonidine to promote locomotion in monoamine-depleted mice. Life Sci. 1990;47(19):1729-36.
82. Crossman AR, Peggs D, Boyce S, et al. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology. 1989;28(11):1271-3.
83. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol. 1996;39(5):574-8.
84. Kelsey JE, Mague SD, Pijanowski RS, et al. NMDA receptor antagonists ameliorate the stepping deficits produce by unilateral medial forebrain bundle injections of 6-OHDA in rats. Psychopharmacology (Berl). 2004;175(2):179-88.
85. Kosinski CM, Standaert DG, Counihan TJ, et al. Expression of N-methyl-d-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus. J Comp Neurol. 1998;390(1):63-74.
86. Blanchet PJ, Konitsiotis S, Whittemore ER, et al. Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesia in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther. 1999;290(3):1034-40.
87. Nash JE, Hill MP, Brotchie JM. Anti-parkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp Neurol. 1999;155(1):42-8.
88. Steece-Collier K, Chambers LK, Jaw-Tsai SS, et al. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol. 2000;163(1):239-43.
89. Löschmann PA, De Groote C, Smith L, et al. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol. 2004;187(1):86-93.
90. Rylander D, Recchia A, Mela F, et al. Pharmacological modulation of glutamate transmission in a rat model of l-dopa-induced dyskinesia: effects on motor behaviour and striatal nuclear signaling. J Pharmacol Exp Ther. 2009;330(1):227-35.
91. Nash JE, Fox SH, Henry B, et al. Antiparkinsonian actions of ifenprodil in the MPTP-lesoned marmoset model of Parkinson's disease. Exp Neurol. 2000;165(1):136-42.
92. Nash JE, Ravenscroft P, McGuire S, et al. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates l-dopa-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of l-dopa in the MPTP-treated marmoset model of Parkinson's disease. Exp Neurol. 2004;188(2):471-9.
93. Addy C, Assaid C, Hreniuk D, et al. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. J Clin Pharmacol. 2009;49(7):856-64.
94. Fasano A, Ricciardi L, Pettorusso M, et al. Management of punding in Parkinson's disease: an open-label prospective study. J Neurol. 2011;258(4):656-60.
95. Inzelberg R, Bonuccelli U, Schechtman E, et al. Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord. 2006;21(9):1375-9.
96. Emre M, Tsolaki M, Bonucccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969-77.
97. Litvinenko IV, Odinak MM, Mogli'naya VI, et al. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. Neurosci Behav Physiol. 2010;40(2):149-55.
98. Metman VL, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesia: a 1-year follow-up study. Arch Neurol. 1999;56(11):1383-6.
99. Luginger E, Wenning GK, Bösch S, et al. Beneficial effects of amantadine on l-dopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2000;15(5):873-8.
100. Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord. 2010;25(10):1357-63.
101. Hanaǧasi HA, Kaptanoglu G, Sahin HA, et al. The use of NMDA antagonist memantine in drug-resistant dyskinesia resulting from l-dopa. Mov Disord. 2000;15(5):1016-7.
102. Varanese S, Howard J, Di Rocco A. NMDA antagonist memantine improves levodopa-induced dyskinesia and "on-off" phenomena in Parkinson's disease. Mov Disord. 2010;24(4):508-10.
103. Merello M, Nouzeilles MI, Cammarota A, et al. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol. 1999;22(5):273-6.
104. Engber TM, Papa SM, Boldry RC, et al. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport. 1994;5(18):2586-8.
105. Dupre KB, Eskow KL, Steiniger A, et al. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-dopa-induced dyskinesia and rotational behaviours in the hemi-parkinsonian rat. Psychopharmacology. 2008;199(1):99-108.
106. Paquette MA, Anderson AM, Lewis JR, et al. MK-801 inhibits l-dopa-induced abnormal involuntary movements only at doses that worsen parkinsonism. Neuropharmacology. 2010;58(7):1002-8.
107. Gomez-Mancilla B, Bédard PJ. Effect of nondopaminergic drugs on l-dopa-induced dyskinesia in MPTP-treated monkeys. Clin Neuropharmacol. 1993;16(5):418-27.
108. Wessell RH, Ahmed SM, Meniti FS, et al. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology. 2004;47(2):184-94.
109. Truong L, Allbutt HN, Coster MJ, et al. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA + parafasicular lesions. Brain Res Bull. 2009;78(2-3):91-6.
110. Warraich ST, Allbutt HN, Billing R, et al. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model. Brain Res Bull. 2009;78(2-3):85-90.
111. Morissette M, Dridi M, Calon F, et al. Prevention of levodopa-induced dyskinesias by a selective NR1/NR2B N-methyl-d-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord. 2006;21(1):9-17.
112. Tamim MK, Samadi P, Morissette M, et al. Effect of non-dopaminergic drug treatment on levodopa induced dyskinesia in MPTP monkeys: common implications of striatal peptides. Neuropharmacology. 2010;58(1):286-96.
113. Papa SM, Boldry RC, Enger TM, et al. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 1995;701(1-2):13-8.
114. Nutt JG, Gunzler SA, Kirchnoff T, et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord. 2008;23(13):1860-6.
115. Kanthasamy AG, Kanthasamy A, Matsumoto RR, et al. Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in an experimental model of Parkinson's disease. Brain Res. 1997;759(1):1-8.
116. Brouillet E, Beal MF. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neuroreport. 1993;4(4):387-90.
117. Chan P, Di Monte DA, Langston JW, et al. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J Pharmacol Exp Ther. 1997;280(1):439-46.
118. Sonsalla PK, Zeevalk GD, Manzino L, et al. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J Neurochem. 1992;58(5):1979-82.
119. Kupsch A, Löschmann PA, Suer H, et al. Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice. Brain Res. 1992;592(1-2):74-83.
120. Zuddas A, Vaglini F, Fornai F, et al. Pharmacologic modulation of MPTP toxicity: MK-801: prevention of dopaminergic cell death in monkeys and mice. Ann N Y Acad Sci. 1992;648:268-71.
121. Lange KW, Löschmann PA, Sofic E, et al. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn Schmeidbergs Arch Pharmacol. 1993;348(6):586-92.
122. Blandini F, Nappi G, Greenamyre JT. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann Neurol. 2001;49(4):525-9.
123. Armentero M-T, Fancekku R, Nappi G, et al. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol Dis. 2006;22(1):1-9.
124. Lee MC, Ting KK, Adams S, et al. Characterisation of the expression of NMDA receptors in human astrocytes. PLoS One. 2010;5(11):e14123.
125. Wu HM, Tzeng NS, Qian L, et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology. 2009;34(10):2344-57.
126. Ossola B, Schendzielorz N, Chen SH, et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia. Neuropharmacology. 2011;61(4):574-82.
127. Leaver KR, Allbutt HN, Creber NJ, et al. Neuroprotective effects of a selective N-methyl-d-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease. Clin Exp Pharmacol Physiol. 2008;35(11):1388-94.
128. Ng OT, Chen LW, Chan YS, et al. Small interfering RNA specific for N-methyl-d-aspartate receptor 2B offers neuroprotection to dopamine neurons through activation of MAP kinase. Neurosignals (Epub 2012 Feb 23).
129. Conn PJ, Battaglia G, Marino MJ, et al. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci. 2005;6(10):787-98.
130. Ossowska K, Konieczny J, Wolfarth S, et al. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology. 2001;41(4):413-20.
131. Breysse N, Baunez C, Spooren W, et al. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of Parkinson's disease. J Neurosci. 2002;22(13):5669-78.
132. Dekundy A, Pietraszek M, Schefer D, et al. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull. 2006;69(3):318-26.
133. Ambrosi G, Arementero MT, Levandis G, et al. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Brain Res Bull. 2010;82(1-2):29-38.
134. Johnston TH, Fox SH, McIldowie MJ, et al. Reduction of l-dopa-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther. 2010;333(3):865-73.
135. De Leonibus E, Managò F, Giordani F, et al. Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease. Neuropsychopharmacology. 2009;34(3):729-38.
136. Chen L, Liu J, Ali U, et al. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral amygdala in rats with bilateral 6-OHDA lesions. Brain Res Bull. 2011;84(3):215-23.
137. Hsieh MH, Ho SC, Yeh KY, et al. Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model. Pharmacol Biochem Behav. 2012;102(1):64-71.
138. Gravius A, Dekundy A, Nagel J, et al. Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats. J Neural Transm. 2008;115(12):1609-19.
139. Mela F, Marti M, Dekundy A, et al. Antagonism of metabotropic glutamate receptor type 5 attenuates l-dopa-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem. 2007;101(2):483-97.
140. Yamamoto N, Soghomonian JJ. Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movement and the increases in glutamic acid decarboxylase mRNA levels in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience. 2009;163(4):1171-80.
141. Levandis G, Bazzini E, Armentero MT, et al. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-dopa-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis. 2008;29(1):161-8.
142. Rylander D, Iderberg H, Li Q, et al. A mGluR5 antagonist under clinical development improves l-dopa-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis. 2010;39(3):352-61.
143. Morin N, Grégoire L, Gomez-Mancilla B, et al. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian
144. Grégoire L, Morin N, Ouattara B, et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor 5 antagonist. l-dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord. 2011;17(4):270-6.
145. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesia: results of 2 randomized controlled trials. Mov Disord. 2011;26(7):1243-50.
146. Addex Therapeutics. Geneva, Switzerland [media release]. 2012 Mar 21 [online]. Available from URL: http://www.addextherapeutics.com/investors/press- releases/news-details/article/addex-reports-positive-top-line-phase-iia-data- for-dipraglurant-in-parkinsons-disease-levodopa-indu/ (Accessed 2012 Oct 3).
147. Battaglia G, Busceti CL, Molinaro G, et al. Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci. 2004;24(4):828-35.
148. Vernon AC, Palmer S, Datla K, et al. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur J Neurosci. 2005;22(7):1799-806.
149. Aguirre JA, Kehr J, Yoshitake T, et al. Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP. Brain Res. 2005;1033(2):216-20.
150. Masilamoni GJ, Bogenpohl JW, Alagille D, et al. Metabotropic glutamate receptor 5 antagonist protects domaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain. 2011;134(7):2057-73.
151. Alam M, Danysz W, Schmidt WJ, et al. Effects of glutamate and alpha-2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. Toxicol Appl Pharmacol. 2009;240(2):198-207.
152. Black YD, Xiao D, Pellegrino D, et al. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Neurosci Lett. 2010;486(3):161-5.
153. Dawson L, Chadha A, Megalou M, et al. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intracerebroventricular administration in the reserpine-treated rat. Br J Pharmacol. 2000;129(3):541-6.
154. Murray TK, Messenger MJ, Ward MA, et al. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav. 2002;73(2):455-66.
155. Battaglia G, Busceti CL, Pontarelli F, et al. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology. 2003;45(2):155-66.
156. Matarredona ER, Santiago M, Venero JL, et al. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurochem. 2001;76(2):351-60.
157. Chan H, Paur H, Vernon AC, et al. Neuroprotection and functional recovery associated with decreased microglial activation following selective activation of mGluR2/3 receptors in a rodent model of Parkinson's disease. Parkinsons Dis. 2010;2010. pii: 190450.
158. Corti C, Battaglia G, Molinaro G, et al. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci. 2007;27(31):8297-308.
159. Bruno V, Sureda FX, Storto M, et al. The neuroprotective activity of group II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling. J Neurosci. 1997;17(6):1891-7.
160. Ciccarelli R, Di Iorio P, Bruno V, et al. Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. Glia. 1999;27(3):275-81.
161. Battaglia G, Molinaro G, Riozzi B, et al. Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons. PLoS ONE. 2009;4(8):e6591.
162. Di Liberto V, Bonomo A, Frinchi M, et al. Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain. Neuroscience. 2010;165(3):863-73.
163. Caraci F, Molinaro G, Battaglia G, et al. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultures neurons, whereas dual activation of mGlu2 and mGlu3 is neuroprotective. Mol Pharmacol. 2011;79(3):618-26.
164. D'Alessandro PL, Corti C, Roth A, et al. The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2. Bioorg Med Chem Lett. 2010;20(2):759-62.
165. Caraci F, Battaglia G, Sortino MA, et al. Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic? Neurochem Int. 2012;61(4):559565.
166. Duty S. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br J Pharmacol. 2010;161(2):271-87.
167. MacInnes N, Messenger MJ, Duty S. Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat. Br J Pharmacol. 2004;141(1):15-22.
168. Konieczny J, Wardas J, Kuter K, et al. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclopentane-1, 3,4-tricarboxylic acid on the parkinsonian like akinesia and striatal proenkephalin and prodynorphin expression in rats. Neuroscience. 2007;145(2):611-20.
169. Lopez S, Turle-Lorenzo N, Acher F, et al. Targeting group III metabotropic glutamate receptors produces complex behavioural effects in rodent models of Parkinson's disease. J Neurosci. 2007;27(25):6701-11.
170. Cuomo D, Martella G, Barabino E, et al. Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment. J Neurochem. 2009;109(4):1096-105.
171. Austin PJ, Betts MJ, Broadstock M, et al. Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease. Br J Pharmacol. 2010;160(7):1741-53.
172. Valenti O, Marino MJ, Wittmann M, et al. Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J Neurosci. 2003;23(18):7218-26.
173. Lopez S, Turle-Lorenzo N, Johnston TH, et al. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology. 2008;55(4):483-90.
174. Beurrier C, Lopez S, Révy D, et al. Electrophysiological and behavioural evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 2009;23(10):3619-28.
175. Broadstock M, Ausin PJ, Betts MJ, et al. Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol. 2012;165(4b):1034-45.
176. Marino MJ, Williams DL Jr, O'Brien JA, et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci USA. 2003;100(23):13668-73.
177. Greco B, Lopez S, van der Putten H, et al. Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. J Pharmacol Exp Ther. 2010;332(3):1064-71.
178. Sukoff-Rizzo S, Leonard SK, Gilbert A, et al. The mGluR7 allosteric agonist AMN082 is a monoaminergic agent in disguise? J Pharmacol Exp Ther. 2011;338(1):345-52.
179. Jones CK, Engers DW, Thompson AD, et al. Discovery, synthesis and structure-activity relationship development of a series of N-4-(2,5- dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. J Med Chem. 2011;54(21):7639-47.
180. Jones CK, Bubser M, Thompson AD, et al. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with l-dopa or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther. 2012;340(2):404-21.
181. Bennouar KE, Uberti MA, Melon C, et al. Synergy between l-dopa and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia. Neuropharmacology (Epub 2012 Apr 3).
182. Wierońska JM, Stachowicz K, Palucha-Ponciewiera A, et al. Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant activity, mediated by serotonergic and GABAergic systems. Neuropharmacology. 2010;59(7-8):627-34.
183. Wierońska JM, Stachowicz K, Acher F, et al. Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology (Berl). 2012;220(3):481-94.
184. Lopez S, Bonito-Oliva A, Pallottino S, et al. Activation of metabotropic glutamate 4 receptors decreases l-dopa-induced dyskinesia in a mouse model of Parkinson's disease. J Parkinsons Dis. 2011;1(4):339-46.
185. Betts MJ, O'Neill MJ, Duty S. Allosteric modulation of the group III mGlu receptor 4 provides functional neuroprotection in the 6-OHDA rat model of Parkinson's disease. Br J Pharmacol. 2012;166(8):2317-30.
186. Battaglia G, Busceti CL, Molinaro G, et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci. 2006;26(27):7222-9.